Myristic Acid.

Protein N-myristoyltransferase transfers myristate from myristoyl-CoA onto an N-terminal glycine residue, which is why glycine is the single most co-studied partner in the literature on this fatty acid. The modification anchors the tagged protein to a membrane. This is intracellular enzymology, not a reason to take the two together as supplements, and no absorption or dosing benefit follows from it.

Pantothenic acid is the backbone of coenzyme A, and myristic acid does nothing metabolically until acyl-CoA synthetase converts it to myristoyl-CoA. Every downstream route, oxidation, elongation, or transfer onto protein, runs through that thioester. The dependency is structural rather than dose-responsive in people eating an ordinary diet.

The first step of each beta-oxidation cycle uses an acyl-CoA dehydrogenase with FAD as its prosthetic group, and FAD comes from riboflavin. Long-chain saturated fats such as myristate therefore depend on riboflavin status to be burned rather than stored. The link is cofactor-level biochemistry, not a claim that extra riboflavin changes body fat.

Fatty acids of 14 carbons cannot cross the inner mitochondrial membrane as CoA thioesters and must be handed to carnitine by CPT1. That distinguishes myristic acid from the C8 and C10 fats it often shares a bottle with, which enter largely carnitine-independently. It explains a route, not an outcome.

Long-chain saturated fatty acids released during digestion form poorly soluble calcium soaps in the small intestine, and myristate behaves this way alongside palmitate and stearate. Both partners lose: some fatty acid and some calcium leave in the stool. Anyone pairing a high-calcium product with a saturated fat load should count this as an absorption interaction rather than a benefit.

Dietary myristic acid arrives esterified into triglycerides and is only released once pancreatic lipase cleaves the sn-1 and sn-3 positions. Position on the glycerol backbone therefore changes how much free myristate reaches the brush border. This is digestion mechanics and says nothing about whether more absorption is desirable.

Myristate-rich fats are solid at room temperature and separate out of aqueous products, so phospholipid emulsifiers are added to hold them dispersed. The pairing is about physical stability of the finished product. It is formulation convention, with no metabolic claim attached.

Fat-soluble vitamins need mixed micelles to cross the enterocyte membrane, and any long-chain fat consumed in the same meal supports micelle formation. Coconut and palm kernel fractions rich in myristic acid serve this role in softgel fills. The vehicle effect belongs to the fat as a class rather than to this chain length specifically.

Carotenoid uptake is famously fat-dependent, and a myristate-rich oil base in a capsule fill provides that lipid. What is being measured in such work is a plasma marker of carotenoid appearance, not a health outcome. The same is true in the other direction: a fat-free matrix lowers apparent absorption.

Coconut oil is sold as a medium-chain fat source, yet its myristic acid is a long-chain fatty acid that is re-esterified into chylomicrons and enters through lymph, unlike the C8 and C10 fractions that travel largely by the portal route. A blend of the two behaves as a mixture of two different absorption routes. Read a coconut-derived ingredient list with that split in mind.

Tocopherols are added to oils to intercept lipid peroxyl radicals. Saturated fats such as myristate have no double bonds and are far less prone to that chemistry than the polyunsaturates they are often blended with, so the antioxidant is there mainly for the rest of the blend. The trade-off is that tocopherol added to a saturated base is largely redundant.